Hero background pattern

Developing the right pricing strategy for your product

We use a variety of pricing techniques and approaches to recommend the optimum value-based pricing for your product.

How can we support you:
Payer Insights
Pricing Strategy
BD Commercial Assessments
Tactical Pricing

We can help you

  • Obtain payer and stakeholder insights into the perceived value of your product
  • Identify the optimal price for your product
  • Determine the global pricing strategy
  • Understand payer evidence requirements to support your value-based pricing and reimbursement strategy
  • Conduct commercial assessments for business development assets
  • Implement pricing tactics to optimize post-launch pricing at a list and net price level
Get in touch

Discover the latest insights

market access
Does price vs volume rule apply for CAR-Ts conside…
We explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a…
Read more
World EPA Congress 2024: Implications of indicatio…
The study explores the complexities of pricing and reimbursement for multi-indication products in th…
Read more
World EPA Congress 2024
The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar…
Read more
market access
Is the attractiveness of launch in the UK changing…
This expert article focusses on the new proportionate approach, and the international recognition pr…
Read more
New MHRA procedure can accelerate patient access t…
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has implemented the Interna…
Read more
ISPOR Europe 2023: Are Acute Therapies And Curativ…
We’ve updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos…
Read more
ISPOR Europe 2023: Evaluation and Reimbursement of…
Our study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics …
Read more
orphan drug pricing
Prescription Price Puzzles: The Sky-High Cost of O…
This article explores the significant disparities between the US and Europe regarding orphan drugs a…
Read more
CMS announces first 10 drugs to undergo price nego…
The Centers for Medicare and Medicaid Services has unveiled a list of 10 drugs to undergo Medicare p…
Read more
PMA Insights: Week 29
We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi…
Read more

I really enjoyed working with Remap Consulting and received powerful advice. A small company like ours needs to receive a flexible approach in order start with market access activities, and I am very happy to see you are as flexible as possible with us.

Director of Market Access
Small pharma payer insights for clinical trials

Remap Consulting’s pricing knowledge and support has been critical to the success of our new pricing team. Their combined experience has provided them with ‘real-world‘ knowledge that can support their recommendations. I highly recommend Remap Consulting and am delighted to continue my work with their pricing group.

Senior Director, Head of Global Pricing
Outsourcing pricing activities for large biotech

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.